[A phase II clinical study of cis-diammine glycolato platinum, 254-S, for gastrointestinal cancers. 254-S Gastrointestinal Cancer Study Group].

Abstract

A phase II clinical study of 254-S, a new anticancer platinum complex for gastrointestinal cancers, was conducted by the 254-S Gastrointestinal Cancer Study Group consisting of 16 institutions. 254-S was administered at 100 mg/m2 by intravenous drip infusion. This administration was repeated at 4-week intervals. The cases in which 254-S could be administered at least two times were regarded as complete cases evaluable for tumor response; of 75 cases registered, 53 were complete cases (29 cases with esophageal cancer, 12 with stomach cancer and 12 with colon cancer). As a result, 15 partial responses (PR) were obtained in the 29 patients with esophageal cancer and 1 PR from the 12 patients with stomach cancer, for a 51.7% and 8.3% response rate, respectively. 5 PR (55.6%) were obtained in 9 esophageal cancer patients with prior chemotherapy, including 2 PR in 4 patients previously treated with cisplatin. Major toxic effects observed were hematotoxicity including thrombocytopenia (59.0%), leukopenia (68.9%) and anemia (57.4%) and gastrointestinal toxicity such as nausea and vomiting (63.9%) and anorexia (41.0%); since grade 3 or 4 thrombocytopenia was observed with an incidence of 27.9%, careful monitoring seems to be required during the treatment with this product. Abnormal parameter changes on renal function included elevations of BUN (18.0%) and serum creatinine (9.8%). Based on these results, it was concluded that 254-S is a useful anticancer agent for the treatment of esophageal cancer.

• Authors: T Taguchi, A Wakui, K Nabeya, M Kurihara, K Isono, T Kakegawa, K Ota
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 19 Issue 4 Pg. 483-8 (Apr 1992) ISSN: 0385-0684 [Print] Japan
• PMID: 1558398 (Publication Type: Clinical Trial, English Abstract, Journal Article, Multicenter Study)

Chemical References

• Antineoplastic Agents
• Organoplatinum Compounds
• nedaplatin

Topics

• Antineoplastic Agents (adverse effects, therapeutic use)
• Colonic Neoplasms (drug therapy)
• Drug Administration Schedule
• Drug Evaluation
• Esophageal Neoplasms (drug therapy)
• Humans
• Infusions, Intravenous
• Leukopenia (chemically induced)
• Middle Aged
• Nausea (chemically induced)
• Organoplatinum Compounds (adverse effects, therapeutic use)
• Stomach Neoplasms (drug therapy)
• Thrombocytopenia (chemically induced)